跳至主要内容
临床试验/ISRCTN47114653
ISRCTN47114653已完成未知

An open-label, prospective, comparative trial to assess prostate specific antigen progression on bicalutamide monotherapy versus bicalutamide and dutasteride therapy in patients with advanced and/or metastatic carcinoma of the prostate

Foundation for the Promotion of Urological Scientific Research (STIWU) (The Netherlands)0 个研究点目标入组 150 人开始时间: 2006年11月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
150

研究概览

简要总结

2018 results in https://www.ncbi.nlm.nih.gov/pubmed/27330919 (added 24/01/2020)

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Patients aged 18 years and above
  • 2. Patients with histologically proven prostate cancer
  • 3. Patients with locally advanced carcinoma of the prostate (T3-4, N0-x) or (T0-x, N1-3; N category should be confirmed histologically or cytologically) or metastatic carcinoma of the prostate (M1)
  • 4. Patients with a high (more than 10 ng/ml) PSA level at baseline
  • 5. Written informed consent to participate in the study
  • 6. Life expectancy is at least 12 months

排除标准

  • 1. Patients simultaneously participating in another study
  • 2. Previous or concurrent chemotherapy, 5-alpha reductase inhibitor therapy or hormonal therapy specifically for the treatment of prostate cancer other than temporary neo-adjuvant hormonal therapy administered longer than one year prior to study entry
  • 3. Development of another invasive neoplastic disease during the previous five years, or concomitant presence of another invasive neoplastic disease, except basal cell carcinoma or squamous cell carcinoma of the skin
  • 4. Patients with a history or presence of hepatic or renal disease or other condition known to interfere with metabolism or excretion of drugs
  • 5. Patients with a history of alcohol or drug abuse

研究者

发起方
Foundation for the Promotion of Urological Scientific Research (STIWU) (The Netherlands)

相似试验

An open-label, prospective, comparative trial to... | 临床试验